{
    "clinical_study": {
        "@rank": "127917", 
        "arm_group": [
            {
                "arm_group_label": "Epidural Steroid", 
                "arm_group_type": "Experimental", 
                "description": "40mg depo-medrol with 4ml of 1% lidocaine"
            }, 
            {
                "arm_group_label": "Epidural Prolotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "1ml of 50% generic dextrose, 2ml of normal saline and 2ml of 1% lidocaine"
            }
        ], 
        "brief_summary": {
            "textblock": "Study comparing caudal prolotherapy to conventional steroid for chronic low back pain"
        }, 
        "brief_title": "Caudal Corticosteroid vs. Hyperosmotic Dextrose Injection for Lumbosacral Radicular Pain.", 
        "condition": "no Conditions", 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA\n\n          1. Participants must satisfy diagnostic criteria for lumbar radicular pain at L4 nerve\n             root level or below with consistent MRI or X ray findings.\n\n          2. Evidence of low back pain base upon one or more of the following:\n\n             i. Lumbar back pain episodes lasting greater than 6 months and current pain level is\n             greater than 6/10 on VAS.\n\n             ii. Has received at lest 2 types of ancillary treatment (i.e. physical therapy, oral\n             analgesia, acupuncture, etc.)\n\n          3. Men or women age greater than or equal to 18 years.\n\n          4. No significant alcohol use (7 or fewer drinks per week).\n\n          5. Patient has a history of at least 2 failed epidural CS injections.\n\n        EXCLUSION CRITERIA\n\n          1. Treatment risk factors including one or more of the following:\n\n             i. Unstable or symptomatic cardiac complaints ii. Unstable or symptomatic respiratory\n             complaints iii. Unable to reliably comprehend the protocol or reliably record data\n\n          2. Pregnancy.   A serum pregnancy test must be performed and negative in all women of\n             child bearing potential within 2 weeks prior to enrollment.\n\n          3. History of Malignancy\n\n          4. Any medical (i.e. malignancy, infection, thrombo-embolic states, autoimmune disease,\n             polyneuropathy)  or psychosocial condition that in the opinion of the investigator,\n             could jeopardize the subject's participation, and compliance with the study criteria."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02116075", 
            "org_study_id": "SC2626"
        }, 
        "intervention": [
            {
                "arm_group_label": "Epidural Steroid", 
                "description": "caudal injection of 1ml of 50% generic dextrose, 2ml of normal saline and 2ml of 1% lidocaine", 
                "intervention_name": "Epidural Prolotherapy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Epidural Prolotherapy", 
                "description": "caudal injection of  40mg depo-medrol with 4ml of 1% lidocaine", 
                "intervention_name": "Epidural Steroid", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 14, 2014", 
        "number_of_arms": "2", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pain relief as measured by VAS pain scale.", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02116075"
        }, 
        "responsible_party": {
            "investigator_affiliation": "VA Long Beach Healthcare System", 
            "investigator_full_name": "Naveed Natanzi", 
            "investigator_title": "Resident Physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in the frequency and amount of opioid use.", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Disability score as determined by Oswstery questionnaire.", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "VA Long Beach Healthcare System", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "VA Long Beach Healthcare System", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}